ID: ALA2069411

Max Phase: Preclinical

Molecular Formula: C23H20F3N3O4

Molecular Weight: 459.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(N[C@@H]1COc2cccc(-c3ccc(CO)nc3)c2C1)c1ccc(OCC(F)(F)F)nc1

Standard InChI:  InChI=1S/C23H20F3N3O4/c24-23(25,26)13-33-21-7-5-15(10-28-21)22(31)29-17-8-19-18(2-1-3-20(19)32-12-17)14-4-6-16(11-30)27-9-14/h1-7,9-10,17,30H,8,11-13H2,(H,29,31)/t17-/m0/s1

Standard InChI Key:  DXYBEOOKXLMROC-KRWDZBQOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 459.42

Molecular Weight (Monoisotopic): 459.1406

AlogP: 3.31

#Rotatable Bonds: 6

Polar Surface Area: 93.57

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.85

CX Basic pKa: 4.26

CX LogP: 2.71

CX LogD: 2.71

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.59

Np Likeness Score: -1.05

References

1. Kers I, Csjernyik G, Macsari I, Nylöf M, Sandberg L, Skogholm K, Bueters T, Eriksson AB, Oerther S, Lund PE, Venyike E, Nyström JE, Besidski Y..  (2012)  Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers.,  22  (17): [PMID:22832315] [10.1016/j.bmcl.2012.06.105]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data